Precautions in the Use of Intensity-Modulated Radiation Therapy
Introduction
Intensity-modulated radiation therapy (IMRT) is the latest phase in the evolution of photon-based external beam radiation therapy. It represents a significant improvement over its predecessor, 3-dimensional conformal radiation therapy or 3D-CRT. With IMRT, the radiation beams are subdivided into smaller "beamlets" through the use of a multi-leaf collimator and each beamlet can be modulated in dose-intensity by duration of exposure. In this way, the patient's three-dimensional anatomy can be represented as pixels or voxels, and each such pixel can be assigned a desired dose level. The resultant conformality around the targeted tumor volumes is thereby substantially improved while the adjacent sensitive normal tissues can be more effectively spared from excessive dose. A potential trade-off however, is an increase in the volume of normal tissue exposed to low-dose irradiation. In addition to this increased irradiated volume there is also occasionally an increase in integral dose, the total energy imparted to the patient. While the increased conformality of IMRT should decrease the late toxicity seen with older radiation therapy techniques, the increased volume of normal tissue exposed to lower doses of radiation potentially may lead to unanticipated, previously unobserved adverse effects.
The increased complexity of IMRT delivery occasionally (but not always) requires an increase in the overall delivery time of each administered daily fraction, which in effect decreases the dose-rate of the administered radiation. Although this diminution of radiation dose-rate may further reduce normal tissue toxicity (1, 2) it may have previously unrecognized consequences on tumor control (3) (4) (5) (6) (7) (8) . The increased time of treatment delivery means that the linac is active longer for each treatment, i.e., more linac monitor units are required per fraction. An increase in monitor units is typically accompanied by increased total body exposure due to leakage radiation. Additionally, when high-energy photons are employed, the increase in monitor units can result in induced radioactivity within the linac collimator due to photonuclear reactions (9) (10) (11) . This presents a potential new safety concern to therapy staff as well as patients.
The computerized IMRT treatment-planning process attempts to redistribute radiation dose in efforts to increase conformality to the targeted tumor and avoid high doses to defined normal structures. However a paradoxical increase in skin reactions has been reported (12) with the use of IMRT and unusual clinical effects such as partial loss of mustaches and holes in beards have been seen in head and neck cancer patients secondary to unfamiliar dose-distributions generated by IMRT planning. With any external beam radiotherapy technique, including IMRT, the increased conformality comes with the potential for "geographic miss" due to organ motion and patient positioning. Also, the emphasis on avoiding high dose to nearby normal tissues can affect the dose-volume histogram (DVH) for the targeted tumor. It is not uncommon to observe an extended low dose "cold shoulder" on the DVH, wherein a small portion of the tumor can receive considerably less than the full prescription dose. In principle this could have a negative impact on tumor control (13).
In this review we discuss some of these various theoretical and observed potential concerns associated with the use of IMRT, along with their clinical relevance and ways we might address such issues.
Radiation Safety Concerns
During delivery of IMRT, the linear accelerator collimator leaves may move in and out of the primary photon beam in a complicated pattern repeatedly during a treatment in order to achieve the desired dose intensity to targeted areas within the patient's body. This complex delivery of radiation is often accompanied by an increase in the required linac monitor units. As a result, there is prolonged exposure of the collimator leaves to the primary photon beam. If the incident photons are of sufficient energy, one consequence of this prolonged exposure can be photoactivation of elements within the collimator itself. This results in the generation of daughter products that are radioactive and could increase radiation exposure to technical and therapy staff as well as patients. Elements within the collimators that are involved in such reactions include 28 Al, 56 Mn, and 24 Na. There is a threshold energy below which photonuclear activation does not occur that differs for each susceptible element but generally exceeds 8 MeV. Therefore, IMRT utilizing highenergy photons may, in principle, be capable of inducing activity within the collimator, depending on its composition. Rawlinson et al. (9) have estimated that with 18 MV photons and a linac workload of 60,000 monitor units per week, therapy staff would receive about 60 microSv with conventional treatments but possibly up to 330 microSv per week if IMRT were used. Thus, therapy staff doses could be increased nearly 6-fold with IMRT and high-energy photons. Other work has demonstrated differences in the induced activity from one linac brand to another (10, 11). Means of circumventing this concern include avoiding highenergy IMRT whenever possible, and when the need for high-energy photons is unavoidable, scheduling these IMRT patients as late in the day as practical. Although some groups do prefer high energy IMRT (14), investigations have indicated that photons energies greater than 6MV are normally not required when IMRT with multiple fields is used (15). It has also been recommended that linac manufacturers strive to design collimators that have reduced susceptibility to photonuclear activation.
Consideration Regarding the Radiation Intensity Profile and Distribution of Dose
Radiation Carcinogenesis: IMRT produces the most conformal radiation dose-distribution currently possible with photon irradiation. Accompanying the increased conformality in some cases there is an increase in integral dose and irradiated volume. As mentioned earlier, the increased linac monitor units required of IMRT can increase leakage radiation and there can be additional exposure due to photoactivation of the collimator. In head and neck IMRT using 6 MV photons, estimated total-body dose is increased nearly eight-fold over conventional radiation therapy: 1969 mSv vs. 242 mSv (16). There is potential concern about the theoretical consequences of this increased low dose exposure through IMRT, particularly with regards to radiation carcinogenesis (16) (17) (18) (19) . Hall and Wuu (17) have estimated that IMRT is likely to almost double the incidence of second malignancies compared with conventional radiotherapy from about 1% to 1.75% for patients surviving 10 years and that the absolute numbers may be larger for longer survival and for younger patients.
The most widely accepted model for radiation carcinogenesis is the linear no-threshold (LNT) model, which an extrapola-tion of high dose exposures (such as nuclear accidents and the Hiroshima and Nagasaki bombs) down to low doses. This is an extremely controversial issue however and there is data both for and against the basic LNT model. Data from single cell microbeam irradiation experiments using alpha particles has demonstrated that the nucleus is not the sole target capable of causing death or transformation of a cell. Similar experiments have also demonstrated that irradiation of neighboring cells may be capable of inducing transformation and apoptosis within the non-irradiated cells, via the so-called bystander effect (20), which is discussed further in the following section. Such findings suggest that the LNT hypothesis may substantially underestimate the potential of low dose radiation exposure. On the other hand, microbeam alpha particle irradiation experiments have also revealed that there is significantly less oncogenic potential of exactly one alpha particle traversal per cell compared to a Poisson-distributed average of one alpha particle traversal per cell (21). In these experiments it was found that exactly one alpha particle per cell was no different in oncogenic potential than the non-irradiated controls. This implies that the majority of oncogenic transformations stem from the minority of cells that have experienced multiple traversals and that a single traversal produces little or no effect. This data suggests that the LNT model overestimates the risk of low-level radiation exposure and casts doubt on the validity of extrapolating from high doses down to exposures of one alpha particle per cell. Recent in vitro evidence that human fibroblasts are surprisingly inefficient at repairing double-strand DNA breaks following low doses of photon radiation but do show efficient repair at higher doses or repeated low dose exposures (22). Survival rates of these cells are diminished following low doses, consistent with low-dose hyper-radiosensitivity. From the organismal perspective however, it may be that removal of cells damaged by low dose irradiation is a means of decreasing the risk of carcinogenesis -it may be wiser for the organism to remove cells damaged by low dose irradiation than to attempt repair and risk the persistence of mutations.
Although there are various predictions about the carcinogenic potential of IMRT, the only way to truly assess this is through careful collection and analysis of actual data. The sophisticated process of IMRT allows reconstruction of the integral dose and irradiated volume that can be retrospectively analyzed. It would be valuable for institutions to prospectively collect data on these variables in patients definitively treated with IMRT techniques as serial and helical tomotherapy (13). In this fashion, data can be accumulated that will hopefully allow investigators to assess the true impact (if any) of the increased low dose exposure associated with IMRT.
Adverse Acute Effects: The larger volume of normal tissue occasionally irradiated to low doses when using IMRT has led to some further speculation about possible complica-tions. One mechanism whereby this might occur is through low dose hyper-radiosensitivity. At doses under 0.1 Gy several cell lines have exhibited a paradoxical in vitro decrease in survival that deviates from predictions made by extrapolation of cell-survival curves at higher doses. Following doses above ∼0.3 Gy there is an increase in radiation resistance up to about 1.0 Gy, beyond which the cell-survival curve then assumes the typical downward-bending shape. Associated with this, is a counter-intuitive "reverse fractionation effect" whereby over five days 0.4 Gy three times daily might prove more cytocidal than 1.2 Gy once daily, for instance. Joiner initially proposed that DNA repair mechanisms are not triggered at very low doses, resulting in decreased cell survival (24). This appears consistent with observations of Rothkam et al. (22) that low dose radiationinduced double strand DNA repair is surprisingly inefficient. Cell cycle investigations by Marples and colleagues (25) demonstrated low dose hypersensitivity in asynchronous and G2-phase enriched cell populations but found no hypersensitivity in G1 and S-phase populations. The hypersensitivity in asynchronous cell populations seemed to be explained entirely by the hypersensitivity response of G2phase cells. They concluded that low dose hypersensitivity might be a consequence of radiation-damaged G2-phase cells prematurely entering mitosis.
Another theoretical (but again unproven) concern about the larger volumes of normal tissue that receive low dose radiation exposure via IMRT lies with the bystander effect. Traditional thinking holds that nuclear DNA is the sole or principle target for the lethal effects of irradiation. Data now indicates that the target for radiation effects extends beyond the cell nucleus and even beyond the boundaries of the irradiated cell. Irradiation of a cell can, in certain situations, induce death and damage in non-irradiated adjacent "bystander" cells. Nagasawa and Little (26), who exposed monolayer cell cultures to very low fluences of alpha particles, reported this phenomenon in 1992. While only a small fraction (<1 %) of cell nuclei were actually hit, sister chromatid exchange frequency was increased in up to 40% of cells. Later experiments confirmed DNA mutations in bystander cells (27). Interestingly, further analysis revealed that mutations in bystander cells were mostly point mutations whereas directly hit cells more often exhibited deletions (28). The relevance of the bystander effect and low dose hypersensitivity in radiation therapy is still uncertain. Anecdotally, many physicians noted unanticipated complications during the initial clinical application of head and neck IMRT, such as increased skin erythema in unexpected places and painful lip irritation. While some thought this could be a manifestation of the bystander effect or low dose hypersensitivity, it now appears these effects have a more mundane explanation that lies with the unfamiliar dose-distributions sometimes generated by IMRT planning.
Considerations Regarding Potential Impact on Tumor Control
Organ Motion, Cold Spots and the "Cold Shoulder" on the DVH: With IMRT or any external beam radiotherapy technique that improves conformality around targeted areas, there is an increased risk of "geographic miss" due to variations in patient position from day-to-day as well as internal organ motion. For maximal benefit, adequate patient immobilization and consideration of organ motion must be accounted for. These issues are being addressed with improvements in immobilization technology and imageguidance such as transabdominal ultrasound for prostate localization, radiocamera-based positional adjustments for brain tumor and head and neck cancer patients, CT-based image guidance (23, 29, 30) and approaches that address respiratory motion (35) . While IMRT significantly improves the conformality of the radiation dose-distribution around targeted tumor volumes and successfully decreases high dose exposure of surrounding normal tissues, an occasional consequence of this tighter conformality is a small volume of tumor that receives less than the prescribed dose. Graphically this is represented by a "cold shoulder" or "cold tail" on the DVH that can extend quite some distance (Fig.  1 ). Tomé and Fowler (13) have investigated the potential significance of this and found that if the dose deficit to even a tiny volume exceeds 20%, a serious loss of tumor control probability may result. Importantly, simply increasing the prescription dose often cannot compensate for a substantial dose deficit to a volume as low as 1% of the tumor volume. That is, if one misses the edge of the target, boosting the dose cannot compensate for this miss. Commonly used prescription constraints such as requesting that "90% of the maximum dose is delivered to at least 95% of the tumor target volume" may not be adequate. Such a prescription specification could result in 5% of the tumor being underdosed, and is very different from specifying that all of the tumor volume must receive at least 95% of the prescribed dose. To avoid this potential danger, Tomé and Fowler (13) IMRT plan should equal or exceed the prescription dose. In this fashion, deep cold spots in the tumor volume are avoided. Further modeling (31) showed that deliberate nonuniform dose distribution within the gross tumor volume might significantly improve tumor control probability (TCP). For example, in certain situations up to a 75% improvement in TCP may be possible if a 60-80% subvolume of the tumor could be boosted in dose. Boost doses to the subvolumes may not have to be drastic, as there generally appears to be a plateau in TCP above boost ratios of 1.2-1.3. This selective boosting of tumor subvolumes may additionally enable steeper dose-gradients outside the target to be achieved.
As commercial planning systems for IMRT evolve, this problem of cold shoulders or tails on the DVH will hopefully diminish, since this is not an inherent limitation of IMRT but rather exists due to the dose constraints typically set. As the available optimization algorithms improve and experience is gained in setting dose constraints, cold tails and shoulders may be less frequently observed.
Influence of Effective Radiation Dose-rate:
While it is generally assumed that the increased radiation doses delivered via IMRT will ultimately result in greater rates of tumor control and survival, this is not yet proven in prospective trials. Although complications generally do appear diminished with IMRT, this should not come at the expense of diminished tumor control. Although the total doses prescribed and delivered through IMRT are higher than previously possible, the delivery of each daily fraction can be prolonged compared to older techniques. This prolongation of fraction delivery time possibly may have a deleterious impact on tumor control (3) (4) (5) (6) (7) (8) . It is conceivable that the increased total doses being delivered now with IMRT will prove less beneficial for local control than anticipated. If future analyses reveal this to be the case, the question will arise of whether dose escalation through IMRT is of little merit, or if perhaps the lower dose-rate of IMRT is less effective than conventional dose-rate radiotherapy. The heterogeneity in doserates from one institution to another may obscure the results of IMRT-based clinical trials currently underway.
Another variable lies in the fact that not all IMRT techniques that lower overall dose-rate do so in a similar fashion. For example, in the "step-and-shoot" IMRT approach, dose-rate to the entire target is protracted whereas in other techniques, such as helical tomotherapy, dose-rate is high in a given area but not all parts of the target receive radiation simultaneously.
Dose-rate issues may be of particular concern for prostate cancer because the radiobiological α/β ratio appears low (7). Typically only the β component of radiation damage is repairable. Therefore, when α/β is low, as in prostate cancer and most late-responding normal tissues, the β component is relatively large and there is a higher capacity for repair. Tissues with low α/β ratios are relatively more affected by fraction size and dose-rates. In such situations, it can be expected that protracted radiotherapy fractions may be sparing of late normal tissue effects but may also be deleterious to tumor control. Although dose-rate may be of greatest theoretical concern for prostate cancer due to its low α/β ratio, other cell lines with higher α/β ratios have also exhibited dose-rate effects in vitro. Benedict et al. (32) irradiated U-87MG human glioma cells to doses ranging between 6-18 Gy over various total times ranging from 16 minutes to 3 hours and observed significant differences in biological effect. This finding is relevant to stereotactic radiosurgery for brain tumors where dose-rates can also vary considerably from one institution to the next. Mu et al. (5) performed in vitro studies using V79 cells irradiated to 2 Gy, a dose more relevant to fractionated external beam radiotherapy. They noted substantial dose-rate effects when the period of irradiation was changed from 1 minute to 10 or 20 minutes. This time-scale is comparable to the differences in time between conventional radiotherapy versus complicated IMRT plans. Morgan et al. (33) specifically evaluated the biological effectiveness of various in vitro irradiation schemes designed to mimic conventional versus IMRT treatments. Using human RKO cells and human-hamster hybrid GM10115 cells, they compared simulated "conventional" irradiations (∼2 Gy in 3 exposures of 66.7 cGy/exposure separated by 2 minute intervals for a total of 6 minutes) versus simulated "IMRT" irradiations (∼2 Gy in 7 exposures of 29 cGy/exposure separated by 3 minute intervals for a total of 20 minutes). In both cell lines, the "IMRT" protocol resulted in increased clonogenic survival compared to the "conventional" protocol. This data again suggests that prolongation of the time to deliver a fraction of radiation can impede tumor control.
Radiobiological modeling also suggests that prolonged fractions may have clinically relevant detrimental effects on tumor control (4-6). Recent in vitro experiments with murine EMT6 and SCCVII cells have confirmed a decrease in biological effectiveness when a given dose of radiation is administered in an interrupted fashion compared to a continuous exposure (8). The authors recommended dose modifications to compensate for such interruptions. Presently, there is insufficient data to determine precisely what the necessary dose compensation should be. In fact, recent preliminary work from this group has suggested much less impact of radiation interruption in vivo than predicted from their in vitro data (34) . The investigators hypothesize that the decrease in sublethal damage repair due to intermittent exposures may be offset by the effects of reoxygenation in vivo. Until further investigation clarifies this matter, one practical suggestion is that whenever possible, radiotherapy fractions be delivered within a time span similar to what has been used previously with conventional radiation therapy and when prolonged fractions are unavoidable, detailed records should be kept so that any possible impact can be detected and analyzed (4).
Unusual and Unexpected Clinical Observations:
Although there are theoretical reasons why IMRT might lead to unusual acute complications such as the bystander effect and low dose hypersensitivity, such concerns have not yet been confirmed. Early in the application of IMRT some clinicians observed unfamiliar adverse effects in head and neck cancer patients such as partial loss of mustaches, holes in beards, increased oral mucositis, nasal bleeding and dryness, and increased skin erythema in unusual places. Although some such effects could possibly be due to low dose hypersensitivity, a more likely and mundane explanation can be identified through careful examination of the radiation dose-distributions generated by the IMRT planning process. Not infrequently, multiple radiation beams will be approaching the patient in a more tangential fashion with IMRT than with conventional treatment planning; this can lead to a higher skin dose than is customary. Lee et al. demonstrated an increased skin dose of about 19% and 27%, with and without a thermoplast mask, respectively (12). These investigators suggested contouring the skin as a sensitive structure to which high dose should be spared during the inverse planning process. In this fashion, the volume of skin that received >45 Gy was reduced by about 20%. The target-to-skin distance can also pose a problem. The IMRT optimization algorithm will endeavor to place the prescribed dose in the buildup region (12). This can cause high-grade skin erythema, especially in head and neck cancer patients, which would be difficult to explain without knowing the specific computer-generated physical aims of the IMRT optimization process. If the target actually comes close to the skin surface it is recommended that bolus be applied.
As computer algorithms attempt to improve tumor dose conformality and minimize normal tissue irradiation, dose can be redistributed to various locations. Unless an anatomical area is contoured by the physician (or others) and a dose restriction is imposed, the computer algorithm may create hot spots of considerable magnitude in unexpected locations (Figure 2 ). With IMRT for prostate cancer, such hot spots could result in subcutaneous fibrosis or focal muscle damage that might not have been anticipated with conventional or 3D treatment planning. Simply inspecting the DVH or viewing the dose distribution around the prostate and adjacent organs may not reveal these hot spots (Figure 3) . Therefore with IMRT, it is prudent to view every CT slice of the computergenerated plan, even if they are remote from the tumor target. The presence of hot spots in unusual locations can then be identified and corrected if necessary, or ignored if deemed to be of little clinical relevance. In some situations as in head and neck cancer patients, additional efforts such as contouring the larynx, lips, tongue, or entire oral cavity and imposing dose limitations may be particularly worthwhile.
Conclusions
Thanks to the vastly improved conformality of radiation dose-distribution, IMRT allows dose escalation and implementation of novel dose-fractionation schemes previously considered impossible or too risky. However, clinicians would be disheartened to find that after 5 or 10 years of clinical application, the net value was less than expected because the radiation delivery dose-rate was lower and less biologically effective than previously. Until additional research clarifies this issue further, to maximize benefit, daily fraction duration should be kept as short as practical (i.e., comparable to duration of conventional treatments) and plans that would take ≥ 30 minutes to implement should generally be rejected.
In circumstances in which protracted delivery time is unavoidable or seems to have acceptable advantages, careful records should be kept and patients followed to ascertain if this theoretical risk of diminished tumor control is indeed real. Also, due to the relatively longer treatment time and increased linac monitor units required with IMRT, induced radioactivity in the collimator could become a radiation safety issue. IMRT with photon energies <18 MV can minimize this concern. In most circumstances, IMRT with 6 MV photons provides adequate dose-distributions and reduces potential phoactivation. When high-energy photons are required, it may be best to administer these treatments toward the end of the day to reduce unnecessary exposure to other patients and personnel. Linac manufacturers should consider this potential concern when designing collimators. In an effort to maximize tumor control, each IMRT treatment plan should be carefully reviewed to assure that the low-dose "cold tail" on the DVH is not significant. One means of assuring this is to require that the EUD exceed or equal the prescription dose. Care must be also taken to avoid adverse effects by being on the lookout for hot spots in unusual places when reviewing IMRT plans. With IMRT plans, it is prudent to review every CT slice to confirm that hot spots are not present in unusual anatomical locations that could lead to unanticipated acute reactions. It is also helpful to review where the lower isodose curves lie following the redistribution of dose by the IMRT planning algorithm. Additional efforts such as contouring normal tissues and imposing dose restrictions may be valuable. Clinical judgment is needed to reject plans that might lead to adverse complications. With IMRT or any highly conformal radiation therapy approach, increased attention to patient immobilization and organ motion is advisable.
Because IMRT can increase the irradiated volume there is the theoretical potential for an increase in secondary malignancies and systematic studies should be performed to formally investigate this. Studies should also investigate the possibility of complications associated with the larger amount of normal tissue receiving low doses of radiation with IMRT due to the bystander effect and low-dose hyper-radiosensitivity. Any such findings should be tempered by clinical relevance and prioritized. It should be kept in mind that failure to control the primary cancer could be considered a devastating and lethal "complication" of any treatment. IMRT holds the promise of reducing this complication as well as many others -if properly and wisely implemented.
